Conditions: Bladder Cancer Transitional Cell Bladder Cancer Urethra Cancer Ureter Cancer Renal Pelvis Cancer
Keywords: Anti-mitotic Eg5 Inhibitor Kinesin Spindle Protein Inhibitor Urothelial Cancer Bladder Cancer Renal Pelvis Cancer Urethra Cancer Ureter Cancer Recurrent Advanced Stage IV
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 54
Healthy volunteers: no

Brief summary:
The purpose of this Phase II study is to determine if AZD4877, an experimental drug that is a novel anti-mitotic agent (Eg5 or Kinesin Spindle Protein inhibitor that interferes with tumor cell division leading to tumor growth), can reduce tumor sizes in patients with bladder cancer

Detailed description:

Arms:
arm 1: Single agent AZD4877

Interventions: intervention 1: AZD4877
Intervention descriptions: intervention 1: Intravenous (IV)25mg/weekly

Protocol document: